CHALICE MEDICAL LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +18.2%

  £9,509,871 → £11,244,920

• Cash

  +139.3%

  £296,962 → £710,734

• Net assets

  +42.8%

  £3,771,009 → £5,384,938

• Employees

  +11.2%

  89 → 99

• Operating profit

  +954%

  £94,322 → £994,131

• Profit before tax

  +2,289.2%

  -£38,264 → £837,676

• Wages

  +6%

  £2,573,261 → £2,728,722

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. CHALICE MEDICAL LIMITED 1998-10-15 → present
2. ACREBRAE LIMITED 1998-09-03 → 1998-10-15

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Cooper Parry Group Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.”

Significant events

• “Turnover increased by 18% to £11.2m, this exceeded forecasts for the second consecutive year. Following a comprehensive financial review, gross profit margin improved to 33% (FY24: 28%), resulting in a 37% increase in gross profit to £3.7m (FY24: £2.7m).”
• “During FY25 we increased ECMO market share through the US launch of the CMO8 oxygenator. UKCA and EU MDR approvals were also obtained for the CMO8, and the first UK clinical use of the CMO8 occurred in September 2025.”
• “Chalice is proud to be among the first companies to achieve full MDR approval across its product range, a testament to the expertise of our regulatory and quality teams. Active pursuit of FDA registration for additional products will enable further growth opportunities in the US.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

3

last 24 months

Officers appointed

2

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.